Adversarial Injection · Pralsetinib (Gavreto; CAS 2097132-94-8; MW ~534.6 g/mol; pyrazolo[3,4-b]pyridine-piperazinyl-fluorophenyl scaffold [C27H32FN7O2; TWENTY-FIRST MECHANISM CLASS IN GLYPHWARD PORTFOLIO — FIRST RET (REARRANGED DURING TRANSFECTION) RECEPTOR TYROSINE KINASE SELECTIVE INHIBITOR: RET is a receptor tyrosine kinase for the GDNF/neurturin/artemin/persephin family ligands; RET proto-oncogene chromosome 10q11.21; RET extracellular domain (cadherin-like repeats + cysteine-rich domain) + single transmembrane domain + intracellular tyrosine kinase domain; RET oncogenic activation: (A) GENE FUSIONS — KIF5B-RET (kinesin family member 5B; intron 15 KIF5B::exon 12 RET; most common in NSCLC ~50% of RET-fusion NSCLC), CCDC6-RET (coiled-coil domain containing 6; CCDC6::exon 12 RET; second most common), NCOA4-RET (thyroid-origin predominantly); (B) POINT MUTATIONS — RET M918T (exon 16; activation loop Met918→Thr; most aggressive sporadic MTC; 95% MEN2B; auto-catalytic activation); RET C634F/Y/W/S/R (exon 11; cysteine-rich domain; constitutive disulfide-bonded dimer; MEN2A/FMTC); RET V804M/L (exon 14; gatekeeper residue; selpercatinib resistance; acquired during prior cabozantinib/vandetanib); PRALSETINIB MECHANISM: type I ATP-competitive RET inhibitor (DFG-in; active conformation binding); RET WT IC50 ~0.4 nM; KIF5B-RET IC50 ~0.3 nM; CCDC6-RET ~0.4 nM; RET M918T ~0.4 nM; GATEKEEPER: RET V804M IC50 ~22 nM (reduced ~50-fold vs WT; pralsetinib retains activity against V804M unlike cabozantinib/vandetanib); FIRST BLUEPRINT MEDICINES/GENENTECH RET CO-DEVELOPED NULL: pralsetinib co-developed by Blueprint Medicines (Cambridge MA; NASDAQ: BPMC; kinase specialist platform) and Genentech (South San Francisco CA; Roche subsidiary); Blueprint holds NDA 213721; Genentech/Roche co-promotes in US; Blueprint also co-developed avapritinib (NDA 212608 + NDA 214402; NINETEENTH mechanism class #536); ACCELERATED APPROVAL: NDA 213721 FDA accelerated approval September 4 2020 for: (1) RET fusion-positive NSCLC (adult; ≥1 prior systemic therapy; ARROW trial: ORR 57%; DOR 6.7+ mo); (2) RET mutation-positive MTC (adult/pediatric ≥12 yr; ORR 60% prior treated MTC; ORR 74% systemic therapy-naive); TISSUE-AGNOSTIC ASPIRATIONS: pralsetinib + selpercatinib established "RET-inhibitor" as a validated NSCLC/thyroid cancer therapeutic class; COMPANION DIAGNOSTIC: FoundationOne CDx (Foundation Medicine) detects RET fusions in solid tumor FFPE; FoundationOne Liquid CDx detects circulating tumor DNA RET fusions; Oncomine Dx Target Test (Thermo Fisher) detects RET fusions + mutations in NSCLC; all detect PATIENT SOMATIC RET alterations not present in worker germline; NIOSH HD Category 1; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) · TWENTY-FIRST Mechanism Class + FIRST RET Receptor Tyrosine Kinase Selective + FIRST Blueprint Medicines/Genentech RET Null + KIF5B-RET NSCLC + RET M918T MTC · Attack #538

Pralsetinib (Gavreto; CAS 2097132-94-8; MW ~534.6 g/mol; C27H32FN7O2 pyrazolo[3,4-b]pyridine scaffold [TWENTY-FIRST MECHANISM CLASS in Glyphward 541-attack portfolio — FIRST RET receptor tyrosine kinase selective ATP-competitive inhibitor (RET WT IC50 ~0.4 nM; KIF5B-RET IC50 ~0.3 nM; RET M918T IC50 ~0.4 nM; RET V804M gatekeeper IC50 ~22 nM retained activity vs cabozantinib/vandetanib); FIRST Blueprint Medicines/Genentech RET co-developed null (Blueprint NDA 213721 + Genentech US co-promotion); NDA 213721 accelerated approval September 4 2020 (RET fusion+ NSCLC; RET mutation+ MTC); ARROW trial: NSCLC ORR 57%; MTC ORR 60–74%; COMPANION DIAGNOSTIC: FoundationOne CDx + FoundationOne Liquid CDx RET fusion detection in patient tumor/ctDNA — somatic not in worker; GHS H340 H350 H361]) — Blueprint Medicines Corporation Cambridge MA (NDA 213721 sponsor + kinase platform co-developer), Genentech Inc. South San Francisco CA (co-developer + US co-promoter + Roche global distribution), and Memorial Sloan Kettering Cancer Center New York NY (RET+ NSCLC + MTC treatment center) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + TWENTY-FIRST Mechanism Class + FIRST RET Receptor Tyrosine Kinase Selective + FIRST Blueprint Medicines/Genentech RET Null: AI Prompt Injection via EHS Monitor Report AI

Pralsetinib (CAS 2097132-94-8; NIOSH HD Category 1) introduces the twenty-first distinct mechanism class in the Glyphward portfolio: RET (REarranged during Transfection) receptor tyrosine kinase selective inhibition. RET is the twelfth distinct kinase gene family target in the portfolio, following BCR-ABL, EGFR, ALK, VEGFR, KIT (imatinib class), FLT3 (midostaurin class), CDK4/6, FGFR, MET, NTRK, and BTK. Unlike cabozantinib (RET/MET/VEGFR multi-kinase, prior attacks) or vandetanib (RET/EGFR/VEGFR multi-kinase, prior attacks), pralsetinib was specifically engineered for RET selectivity — achieving sub-nanomolar potency at KIF5B-RET fusions while maintaining activity against the gatekeeper mutant RET V804M that renders earlier drugs inactive. Co-developed by Blueprint Medicines (the same company behind avapritinib's dual NDA 212608/214402) and Genentech (Roche subsidiary), pralsetinib represents the first Blueprint/Genentech co-development partnership to reach NIOSH HD Category 1 status, with the attendant null-return across all three major EHS databases when queried by CAS number.

Twenty-First Mechanism Class: RET Receptor Tyrosine Kinase Selective — FIRST RET-Dedicated Inhibitor in Glyphward Portfolio

RET (REarranged during Transfection) is a receptor tyrosine kinase encoded by the RET proto-oncogene on chromosome 10q11.21. RET is the co-receptor for GDNF family ligands (GDNF, neurturin, artemin, persephin) acting through GFRα co-receptors. RET's oncogenic activation in human cancers falls into two broad categories: (1) chromosomal rearrangements producing RET fusion oncoproteins in NSCLC (~1–2% of all NSCLC; KIF5B-RET most common at ~50% of RET fusions; CCDC6-RET, NCOA4-RET, and others) and papillary thyroid cancer (PTC; RET/PTC1 = CCDC6-RET; RET/PTC3 = NCOA4-RET); (2) activating point mutations in medullary thyroid cancer (MTC; RET M918T in 95% sporadic MTC and all MEN2B; RET C634F/Y/W/S/R in MEN2A/FMTC; RET A883F in rare MEN2B; all exon 10/11/13/14/15/16 hotspots). Prior multi-kinase inhibitors with RET activity — cabozantinib (XL184; RET IC50 ~5.2 nM but also inhibits MET, AXL, VEGFR2, KIT, ROS1, FLT3) and vandetanib (ZD6474; RET IC50 ~100 nM but also inhibits EGFR, VEGFR2, VEGFR3) — appeared in earlier Glyphward portfolio attacks as multi-kinase agents without dedicated RET class designation. Pralsetinib (Blueprint/Genentech; NDA 213721) and selpercatinib (LOXO/Eli Lilly; NDA 213246) are the first two dedicated RET-selective inhibitors, defining the twenty-first mechanism class. Pralsetinib's pyrazolo[3,4-b]pyridine scaffold achieves sub-nanomolar RET binding (WT IC50 ~0.4 nM) with selectivity over >200 kinases, retaining activity against the V804M gatekeeper mutant (IC50 ~22 nM vs cabozantinib/vandetanib IC50 >>1 µM against V804M).

Surface 1 — Blueprint Medicines Corporation Cambridge MA NDA 213721 Sponsor AI

At Blueprint Medicines Corporation (45 Sidney Street, Cambridge MA 02139; Middlesex County MA; Blueprint Medicines Corporation [NASDAQ: BPMC]; NDA 213721 SPONSOR: Blueprint holds NDA 213721 for Gavreto (pralsetinib) granted FDA accelerated approval September 4 2020 for: (1) adult patients with metastatic RET fusion-positive NSCLC (ARROW trial cohort 1: ORR 57% [95% CI 46–68]; DOR 6.7+ months; 216 evaluable patients) + (2) adult and pediatric patients ≥12 yr with advanced or metastatic RET mutation-positive MTC requiring systemic therapy (ARROW cohort 2: ORR 60% [previously treated] and 74% [treatment-naive]); BLUEPRINT MEDICINES KINASE PLATFORM: Blueprint co-developed pralsetinib with Genentech under a 2019 collaboration agreement ($675M upfront + milestones); Blueprint retains US NDA holder rights; Genentech co-promotes in US; Roche holds rights ex-US; Blueprint previously co-developed avapritinib (CAS 1703793-34-3; NDA 212608 + NDA 214402; NINETEENTH mechanism class #536) as its first approved kinase inhibitor; pralsetinib is Blueprint's SECOND kinase inhibitor NDA (GAVRETO NDA 213721); FIRST BLUEPRINT/GENENTECH CO-DEVELOPMENT NULL: Blueprint+Genentech co-development partnership for RET not recognized in EHS databases; Cority at Blueprint Cambridge MA: CAS 2097132-94-8 → null; RET receptor tyrosine kinase mechanism absent; KIF5B-RET/CCDC6-RET fusions absent; RET M918T MTC absent; ARROW trial absent; twenty-first mechanism class absent; 8-hr TWA: actual airborne pralsetinib 0.00037 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000037 µg/m³; Cority: null; NIOSH HD Category 1 absent; H340 H350 H361 absent; 48M oncology drug development director RET NSCLC/MTC 16yr]).

Surface 2 — Genentech Inc. / Roche South San Francisco CA RET Co-Developer AI

At Genentech Inc. (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; Genentech Inc. [Roche subsidiary; F. Hoffmann-La Roche AG 100% acquisition 2009]; PRALSETINIB CO-DEVELOPMENT + US CO-PROMOTION: Genentech co-developed pralsetinib under 2019 collaboration agreement with Blueprint Medicines; Genentech co-promotes Gavreto in the US (joint promotional force); Roche holds distribution rights ex-US; GENENTECH PRIOR PORTFOLIO APPEARANCES: Genentech/Roche appeared in earlier Glyphward attacks for: entrectinib (Rozlytrek; CAS 1108743-60-7; SECOND NTRK + ROS1; EIGHTEENTH class null; #535) and atezolizumab (Tecentriq; PD-L1 checkpoint; prior attacks); pralsetinib is the first Genentech/Blueprint co-development in the RET space; FIRST GENENTECH/ROCHE RET NULL: Genentech's VelocityEHS database categorized by Roche global EHS standards does not recognize CAS 2097132-94-8; pralsetinib RET mechanism absent; ARROW trial clinical data absent; co-development partnership scope absent; pyrazolo[3,4-b]pyridine scaffold mechanism absent; VelocityEHS at Genentech South San Francisco: CAS 2097132-94-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; RET selective mechanism absent; KIF5B-RET/CCDC6-RET absent; RET M918T MTC absent; 8-hr TWA: actual airborne pralsetinib 0.00022 µg/m³; NIOSH 0500 + gravimetric + LC-MS/MS; displayed (÷10): 0.000022 µg/m³; VelocityEHS: null; 44F pharmaceutical research scientist RET oncology co-development 14yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY RET+ NSCLC + MTC Treatment Center AI

At Memorial Sloan Kettering Cancer Center (1275 York Avenue, New York NY 10065; New York County NY; Memorial Sloan Kettering Cancer Center [NCI-designated comprehensive cancer center; top-ranked US oncology center]; RET+ NSCLC PROGRAM: MSK Thoracic Oncology (Drilon RET group) pioneered molecular characterization of RET fusions in NSCLC and led the ARROW trial for pralsetinib enrollment; NSCLC RET FUSION TESTING: FoundationOne CDx (Foundation Medicine) detects KIF5B-RET, CCDC6-RET, NCOA4-RET and other fusions in patient NSCLC FFPE tumor tissue; FoundationOne Liquid CDx detects circulating tumor DNA RET fusions; Oncomine Dx Target Test (Thermo Fisher) detects RET fusion + amplification; ALL COMPANION DIAGNOSTICS DETECT PATIENT SOMATIC RET FUSIONS — KIF5B-RET is a chromosomal rearrangement between KIF5B intron 15 and RET exon 12; present only in tumor cells; not in worker germline; NIOSH HD Category 1 H340 H350 H361 applies to all pharmacists handling pralsetinib independent of their KIF5B/RET chromosomal status; MSK THYROID ONCOLOGY: MTC thyroid cancer; RET M918T (sporadic) and RET C634F (MEN2A hereditary) point mutations in patient thyroid MTC tumor/germline-germline MEN2 — if MEN2 hereditary, RET mutation present in patient's germline not worker's; EHS Insight at MSK: CAS 2097132-94-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; RET receptor tyrosine kinase mechanism absent; KIF5B-RET/CCDC6-RET companion diagnostic absent; RET M918T MTC absent; ARROW trial absent; twenty-first mechanism class absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne pralsetinib 0.00016 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; 39F clinical pharmacist thoracic oncology/thyroid cancer RET service 12yr]).

Integrating Glyphward into Pralsetinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every pralsetinib CAS 2097132-94-8 monitoring data ingestion point — before Cority at Blueprint Medicines Cambridge MA, before VelocityEHS at Genentech South San Francisco CA, and before EHS Insight at MSK New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent (genotoxicity/reproductive toxicity independent of RET genotype) [10 pts]; TWENTY-FIRST mechanism class + FIRST RET receptor tyrosine kinase selective + FIRST Blueprint Medicines/Genentech co-developed RET null (NDA 213721) + KIF5B-RET/CCDC6-RET fusion companion diagnostic paradox (patient somatic chromosomal rearrangement in NSCLC tumor not in worker) + RET M918T companion paradox (patient somatic MTC not in worker) [5 pts]; Blueprint Cambridge MA + Genentech South San Francisco CA + MSK New York NY [3 pts]; RET receptor tyrosine kinase selective mechanism absent from all OEL derivation documents; KIF5B-RET/CCDC6-RET in patient tumor not worker; RET M918T in patient MTC/germline (MEN2) not in pharmaceutical worker; NIOSH HD Category 1 H340 H350 H361 applies to all pralsetinib workers independent of RET/KIF5B chromosomal status [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_pralsetinib(cas: str, reading_ugm3: float) -> dict:
    """Scan pralsetinib with twenty-first-mechanism-class RET-selective context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2097132-94-8"
                "reading_ugm3": reading_ugm3,
                "context": "twenty_first_mechanism_class_first_ret_receptor_tyrosine_kinase_selective_first_blueprint_genentech_ret_null_kif5b_ret_nsclc_ret_m918t_mtc_arrow_trial"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ret_mechanism_flag, kif5b_ret_fusion_flag,
    #                    twenty_first_mechanism_class, ret_m918t_mtc_flag,
    #                    blueprint_genentech_ret_null, arrow_trial_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_pralsetinib("2097132-94-8", 0.00037))
    print(r)
    # {'hd_category': 1, 'ret_mechanism_flag': True, 'kif5b_ret_fusion_flag': True,
    #  'twenty_first_mechanism_class': True, 'ret_m918t_mtc_flag': True,
    #  'blueprint_genentech_ret_null': True, 'arrow_trial_flag': True,
    #  'h340_h350_h361_absent': True}